ClinicalTrials.gg
CompletedNCT06143943Updated Nov 22, 2023

Anterior Segment Anatomic Parameters for Risk Profiling of Primary Angle-closure Glaucoma

An observational study in Glaucoma, Angle-Closure, sponsored by Min Ke. Completed at 1 site in China. Open to participants aged 30 Years to 92 Years. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Min Ke · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
168
Ages
30 Years to 92 Years
Sex
All
01

Study summary

The goal of this observational study is to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (PACG). The main question it aims to answer is:

  • Are there new anatomical parameters of the anterior segment of the eye that can be used early for risk profiling for PACG? Researchers will compare PACG and narrow angle groups to see if there are some anatomical parameters that can distinguish the two.
Read the detailed description

We aimed to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (PACG).

This retrospective study included 84 patients with PACG and 84 patients with narrow angles (NA). We collected parametric measurements obtained using anterior-segment optical coherence tomography and IOLMaster 700. Univariate and multivariate logistic regression models were used to compare the ocular parameters between the NA and PACG groups as well as to identify risk factors for PACG. The predictive performance of each parameter was evaluated using the area under the receiver operating characteristic curve (AUROC) analysis.

02

Conditions studied

  • Glaucoma, Angle-Closure
03

In context

Glaucoma, Angle-Closure

91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.

This study's enrollment of 168 is below the median of 225 across 32 observational studies indexed under Glaucoma, Angle-Closure.

Browse Glaucoma, Angle-Closure studies →

Lead sponsor

Min Ke is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 92 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with PACG and anterior chamber angle stenosis were enrolled in this study and excluded from other diseases affecting the structure of the anterior segment of the eye, as well as a history of intraocular surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary angle-closure glaucoma (PACG) was defined as an occlusion angle with peripheral anterior synechiae and intraocular pressure (IOP) > 21 mmHg or associated with glaucomatous optic neuropathy. The following conditions were identified as possible glaucomatous optic neuropathies, including a vertical cup-to-disc ratio ≥ 0.6, vertical cup-to-disc ratio asymmetry ≥ 0.2, optic disc haemorrhage, and visible retinal nerve fibre layer defect.
  2. Participants with narrow angle (NA) were selected from among patients with cataracts. NA was defined as a trabecular-iris angle () \< 15° on anterior segment optical coherence tomography, with the exclusion of glaucomatous optic neuropathy or visual field loss.

Exclusion criteria

Exclusion Criteria:

(1) severe systemic disease, (2) secondary angle-closure glaucoma, (3) other ocular diseases, (4) history of intraocular surgery, and (5) unclear examination images.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
168 participants (actual)
Patient registry
No

Groups and cohorts

  • primary angle-closure glaucoma
  • narrow angle
06

What researchers measure

Primary outcomes

  1. Trabecular scleral-spur angle

    The angle between the line of the corneal endothelium 750 μm from the scleral spur to the scleral spur and the bilateral line of the scleral spur

    Time frame: 2022-11-22 to 2022-12.31

07

Study locations

1 site
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Dec 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Nov 22, 2022
Primary completionActual
Dec 31, 2022
CompletionActual
Feb 28, 2023
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06143943
Lead sponsor
Min Ke
Responsible party
Min Ke (Professor of Treatment, Zhongnan Hospital) — Sponsor-investigator
First posted
Nov 22, 2023
Start date
Nov 22, 2022
Primary completion
Dec 31, 2022
Completion
Feb 28, 2023
Last update
Nov 22, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion